Overall Fundamental outlook

|fundrankingplaceholder|
|techrankingplaceholder|

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Cipla Limited, together with its subsidiaries, engages in the manufacture, development, sale, and distribution of pharmaceutical products in India, the United States, South Africa, and internationally. The company operates through Pharmaceuticals and New Ventures segments. It offers generic and branded generic medicines, vaccines, active pharmaceutical ingredients, and formulations for various therapeutic areas, such as MI, angina, heart disease, pulmonary disease, kidney failure, Alzheimer's disease, hypertension, arrhythmia, lipid abnormalities and diabetes, obesity, central nervous system, HIV/AIDS, respiratory, asthma, urology, oncology, cardio-metabolism, child health, infectious diseases and critical care, hepatitis, women's health, ophthalmology, and neuro psychiatry. The company is also involved in the consumer healthcare, biosimilars, and specialty businesses. Cipla Limited was incorporated in 1935 and is based in Mumbai, India.

Revenue projections:

Revenue projections for CIPLA
Revenue projections for CIPLA

Cipla Limited's revenue projections indicate a decrease from the prior year, which may make investors hesitant. A revenue decline could harm the company's bottom line, prompting investors to be more careful, as lower earnings often signal potential issues with profitability and future performance.

Financial Ratios:

currentRatio 3.443000
forwardPE 22.433458
debtToEquity 1.778000
earningsGrowth -0.546000
revenueGrowth -0.038000
grossMargins 0.655410
operatingMargins 0.094990
trailingEps 47.930000
forwardEps 63.186870

The current ratio for Cipla Limited is 3.443, indicating that the company can service its short-term debt using available cash and assets. This suggests Cipla Limited has strong liquidity, with more than enough resources to meet its immediate financial commitments.
CIPLA's Forward PE ratio is in a good range, reflecting a reasonable balance between stock price and earnings. The stock is not overpriced, leaving room for growth, which suggests potential for investors looking to capitalize on future value appreciation.
Cipla Limited's low earnings and revenue growth point to a likely decrease in profits. This suggests that the company is facing financial difficulties and may struggle to maintain its current level of profitability.
CIPLA's negative gross and operating margins indicate that the company is currently unprofitable at both the production and operational levels. This suggests significant challenges in managing costs and generating revenue, which could impact its overall financial health.
Cipla Limited's forward EPS being higher than its trailing EPS signals anticipated growth in profitability for the current financial year. This suggests that Cipla Limited is on track to improve its earnings, outpacing the previous year's performance and reflecting positive market expectations.

Price projections:

Price projections for CIPLA
Price projections for CIPLA

Cipla Limited's stock price has repeatedly hovered near the lower end of projections. This trend indicates that the company may be facing obstacles in achieving the growth anticipated by analysts.

Recommendation changes over time:

Recommendations trend for CIPLA
Recommendations trend for CIPLA


With analysts showing a buy bias for CIPLA, investors may be more inclined to see the stock as an attractive investment. The favorable outlook could spur increased interest, positioning CIPLA as a safe and profitable place for investors to allocate their funds and seek growth.